Potential Immunological Treatments in COVID-19 Patients
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seemed in Wuhan, China in December 2019. SARS-CoV-2 infection in human was named as coronavirus disease 2019 (COVID-19). It has now infected more than 69 million people worldwide, becoming an epidemic responsible for more than 1,5 million...
Main Authors: | Muhammet Mesut Nezir Engin, Öner Özdemir |
---|---|
Format: | Article |
Language: | English |
Published: |
Duzce University
2021-04-01
|
Series: | Düzce Tıp Fakültesi Dergisi |
Subjects: | |
Online Access: | https://dergipark.org.tr/tr/pub/dtfd/issue/60168/856165 |
Similar Items
-
Immune-related adverse events of biological immunotherapies used in COVID-19
by: Daniela Baracaldo-Santamaría, et al.
Published: (2022-08-01) -
Convalescent (Immune) Plasma Followed by Intravenous Immunoglobulin Infusion in an Adolescent with Severe COVID-19
by: Öner Özdemir, et al.
Published: (2021-08-01) -
Is immunosuppressive therapy an effective treatment for COVID-19? – literature review
by: Barbara Ostrowska, et al.
Published: (2023-05-01) -
Comparison of Tocilizumab and Anakinra in the Treatment of COVID-19: A Single-Center Experience
by: Bengisu Pınar Acat, et al.
Published: (2022-08-01) -
Pharmacology and Adverse Events of Emergency-Use Authorized Medication in Moderate to Severe COVID-19
by: Jen-Yu Hsu, et al.
Published: (2021-09-01)